Treatment of circadian rhythm disorders
AssigneeVanda Pharmaceuticals Inc.
InventorsMarlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
Life of this patent
Estimating the term…
Abstract
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g. blind patients, and to methods of measuring circadian rhythm.
Claims18
A method of treating Non-24 in a patient suffering therefrom, said method comprising internally administering to the patient an effective amount of tasimelteon, wherein the patient is being treated with a CYP3A4 inducer and wherein the effective amount is greater than 20 mg/d.
A method of entraining a patient suffering from Non-24 to a 24 hour sleep-wake cycle in which the patient awakens at or near a target wake time following a daily sleep period of approximately 7 to 9 hours, said method comprising:
- treating the patient by internally administering to the patient an effective amount of tasimelteon.
A method for the chronic treatment of Non-24 in a person who is totally blind comprising orally administering to the person tasimelteon in an amount of 150 to 250 mg once daily about ½ hour to about 1½ hours before the desired bedtime.
Dependencies are inferred from the claim text.